Product Name:2,5,6-Trichloronicotinamide

IUPAC Name:2,5,6-trichloropyridine-3-carboxamide

CAS:142266-62-4
Molecular Formula:C6H3Cl3N2O
Purity:95%+
Catalog Number:CM177898
Molecular Weight:225.45

Packing Unit Available Stock Price($) Quantity
CM177898-100mg in stock ǙǪƥ
CM177898-250mg in stock ǪǙIJ
CM177898-1g in stock IJľŹ
CM177898-5g 1-2 Weeks ǙƈƥŹ
CM177898-25g 3-4 Weeks ľŗŗŗ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:142266-62-4
Molecular Formula:C6H3Cl3N2O
Melting Point:-
Smiles Code:O=C(N)C1=C(Cl)N=C(Cl)C(Cl)=C1
Density:
Catalog Number:CM177898
Molecular Weight:225.45
Boiling Point:
MDL No:
Storage:Store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

MK-1084
Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer. KRAS mutations are one of the most frequently observed mutations in human cancers, making them a crucial target for precision oncology therapy.
MK-1084 is an investigational, oral covalent inhibitor of KRAS G12C, that is found in about 14% of people with non-small cell lung cancer. MK-1084 is currently under Phase 1 evaluation as monotherapy and as combined therapies in patients with KRAS G12C mutant advanced solid tumors.

Related Products